Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-so-familiar routine of meetings, Skype calls, and endless texting has predictably returned, even though this is a short week on this side of the pond. So time to get cracking. We are firing up the coffee kettle and brewing a few cups of stimulation — our flavor of the day is coconut. Meanwhile, here are a few items of interest for you to peruse. Hope you have a productive day and please do keep in touch.

President Trump is backing off his 2016 campaign pledge to negotiate drug prices for Medicare with drug makers, drawing fire from Democrats after months of talks on the issue with Speaker Nancy Pelosi (D-Calif.), The Hill reports. Her staff spent months trying to get White House support for her measure to allow the government to negotiate prices for up to 250 drugs per year, with tough financial penalties for companies that refused to come to the table. But Trump is now publicly bashing the bill, although he has not proposed an alternative.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy